Skip to main navigation Skip to search Skip to main content

Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study

  • Gianantonio Rosti
  • , Tim H. Brümmendorf
  • , Björn T. Gjertsen
  • , Pilar Giraldo-Castellano
  • , Fausto Castagnetti
  • , Carlo Gambacorti-Passerini
  • , Thomas Ernst
  • , Huadong Zhao
  • , Luke Kuttschreuter
  • , Simon Purcell
  • , Francis J. Giles
  • , Andreas Hochhaus
  • IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”
  • University Hospital Aachen
  • Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD)
  • Haukeland University Hospital
  • Miguel Servet University Hospital
  • University of Bologna
  • University of Bologna
  • University of Milano-Bicocca
  • Jena University Hospital
  • Pfizer Inc.
  • Pfizer Regenerative Medicine
  • Developmental Therapeutics LLC

Research output: Contribution to a Journal (Peer & Non Peer) › Article › peer-review

9 Citations (Scopus)

Abstract

In the phase 4 BYOND trial, patients with pretreated chronic myeloid leukemia (CML) received bosutinib (starting dose: 500 mg/day). Efficacy and safety after ≥3 years of follow-up in 156 patients with Philadelphia chromosome–positive chronic phase CML by age and Charlson Comorbidity Index scores (without the age component; mCCI) is reported. Cumulative major molecular response rates at any time on treatment were 73.6%, 64.5%, and 74.1% in patients <65, 65–74, and ≥75 years of age, and 77.9%, 63.0%, and 59.3% in patients with mCCI scores 2, 3, and ≥4, respectively. Patients <65, 65–74, and ≥75 years of age experienced grade 3/4 treatment-emergent adverse events (TEAEs) at rates of 74.7%, 78.8%, and 96.4% and permanent discontinuations due to AEs at rates of 22.1%, 39.4%, and 46.4%, respectively. In patients with mCCI 2, 3, and ≥4, respective rates of grade 3/4 TEAEs were 77.8%, 77.8%, and 86.7%, and permanent discontinuations due to AEs were 25.3%, 33.3%, and 43.3%. In conclusion, a substantial proportion of patients maintained/achieved cytogenetic and molecular responses across age groups and mCCI scores. Older patients (≥75 years) and those with high comorbidity burden (mCCI ≥4) may require more careful monitoring due to the increased risk of TEAEs.

Original languageEnglish
Pages (from-to)126-135
Number of pages10
JournalLeukemia
Volume38
DOIs
Publication statusPublished - 2024
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study'. Together they form a unique fingerprint.

Cite this